Vanku

Reporting best response results tent (and normally persistently poor), that a non-randomised trial is justi?able (see for instance van Glabbeke et al. In this case the potential value savings for policy A1 fall from 2 million to 141,000 per year and in the most optimistic scenario (policy A3) potent...